SQZ Biotechnologies (NYSE:SQZ) issued its quarterly earnings data on Monday. The company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.10, Fidelity Earnings reports.
Shares of SQZ Biotechnologies stock traded up $0.09 during trading hours on Wednesday, hitting $11.56. The company’s stock had a trading volume of 7,972 shares, compared to its average volume of 168,305. The stock has a 50 day moving average price of $12.82. SQZ Biotechnologies has a 12-month low of $11.17 and a 12-month high of $36.49.
Several analysts recently commented on the company. Zacks Investment Research lowered SQZ Biotechnologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 24th. Brookline Capital Management reaffirmed a “buy” rating on shares of SQZ Biotechnologies in a report on Tuesday, March 30th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $33.75.
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
Featured Article: What is Net Asset Value (NAV)?
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.